Text Size

Prevalence of Undiagnosed Chronic Obstructive Pulmonary Disease Sufferers in the Region of Murcia

This study has been completed.
Sponsor:
Collaborators:
Servicio Murciano de salud
Consejeria de sanidad.Direccion general de planificacion, ordenacion sanitaria y farmaceutica e investigacion.
AstraZeneca
Information provided by:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
ClinicalTrials.gov Identifier:
NCT01380470
First received: June 22, 2011
Last updated: June 23, 2011
Last verified: June 2011
History of Changes
  Purpose

The purpose of this study is determine the prevalence of undiagnosed Chronic Obstructive Pulmonary Disease (COPD) in population served and with exposure to cigarettes in the Region of Murcia


Condition
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Prevalence of Undiagnosed Sufferers in Murcia :Cross-sectional Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia:

Primary Outcome Measures:
  • FEV1/FVC,Forced Expiratory Volume 1/ Forced Vital Capacity [ Time Frame: 15 days ] [ Designated as safety issue: No ]

Enrollment: 2627
Study Start Date: February 2010
Study Completion Date: June 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Chronic Obstructive Pulmonary Disease
Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.

Detailed Description:

COPD is a serious, chronic and very disabling, associated with smoking and aging. Therefore it is a preventable and treatable process. It is know to be a pathology under diagnosed and when diagnosis, this is done in advanced stage, resulting to rise to more complication and more severe, in a addition to a high social and economic cost.

Therefore, take out an epidemiological study, observational, multicentre, whose main objective is estimate the prevalence of undiagnosed COPD in population served between 40 and 70 years and exposure to cigarettes in the Region of Murcia.

Other objectives are estimate the proportion of patients already diagnosed, identifying risk factors associated with not previous diagnosis of COPD and describe the history of symptoms in them. Description of therapeutic manage and motivation to give up smoking.

The study was carried out with 120 researcher doctors and 120 researcher nurses from 40 health centers in the Region of Murcia.

Each researcher will select 10 patients for the main objective and 10 for objectives related to manage of COPD.

  Eligibility

Ages Eligible for Study:   40 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.

Criteria

Inclusion Criteria:

  1. Aged between 40 and 70 years of both sexes
  2. With a history of smoking (current or past)
  3. Do not diagnosed with COPD at the time of completion of study

Exclusion Criteria:

  1. Prior diagnosis of COPD or Asthma
  2. A condition prevents performing spirometry
  3. Patients displaced

For those diagnosed with COPD:

Inclusion Criteria:

  • Subject treated in CS there is explicit evidence for the disease

Exclusion Criteria:

  • Subjects who at the time of the consultation arouse suspicion of previously undiagnosed COPD
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01380470

Locations
Spain
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
Murcia, Region de Murcia, Spain, 30003
Sponsors and Collaborators
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Servicio Murciano de salud
Consejeria de sanidad.Direccion general de planificacion, ordenacion sanitaria y farmaceutica e investigacion.
AstraZeneca
Investigators
Principal Investigator: Asensio Lopez Santiago, MD Consejeria de sanidad y consumo, Direccion general de planificacion, ordenacion sanitaria y farmaceutica e investigacion.
  More Information

No publications provided

Responsible Party: Javier Júdez Gutiérrez, Fundación para la Formación e Investigación Sanitaria de la Región de Murcia
ClinicalTrials.gov Identifier: NCT01380470     History of Changes
Other Study ID Numbers: Brisa I
Study First Received: June 22, 2011
Last Updated: June 23, 2011
Health Authority: Spain: Ministry of Health and Consumption

Keywords provided by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia:
Chronic Obstructive Pulmonary Disease
Diagnosis differential
Dyspnea/classification
Dyspnea/etiology

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013